# Foresee Pharmaceuticals

Source: https://onco.cc/companies/foresee-pharmaceuticals/  
OnCo record `foresee-pharmaceuticals` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Foresee is a Taipei biotech whose long-acting leuprolide depot, Camcevi, is an injection for advanced prostate cancer, and which runs phase 3 trials as lead sponsor.

## Summary

Foresee Pharmaceuticals, headquartered in Taipei, Taiwan, developed a ready-to-use six-month leuprolide mesylate depot (Camcevi) for advanced prostate cancer, approved in the United States and Europe, and is developing further hormone and immunology products. It is lead sponsor of several phase 3 trials registered on ClinicalTrials.gov.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Foresee Pharmaceuticals Co., Ltd.; Foresee
- Tags: ctgov-sponsor
- HQ: Taipei
- Type: biotech
- Website: https://www.foreseepharma.com

## Sources

- Official website: https://www.foreseepharma.com
- ClinicalTrials.gov: trials led by Foresee Pharmaceuticals: https://clinicaltrials.gov/search?lead=Foresee%20Pharmaceuticals
- Wikidata: https://www.wikidata.org/wiki/Q140045369

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Leuprolide (leuprorelin) and GnRH agonists](https://onco.cc/drugs/leuprolide/)
- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)

---
JSON: https://onco.cc/api/v1/entities/foresee-pharmaceuticals.json